News briefing: Merck’s Roger Perlmutter buys his first solid tumor TriNKET from Dragonfly; ViGeneron to expand production of eye gene therapy
A little more than 2 years after Merck’s Roger Perlmutter signed off on a deal that would pay Dragonfly up to $695 million for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
